183 related articles for article (PubMed ID: 7869772)
1. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.
van Rhee F; Marks DI; Lin F; Szydlo RM; Hochhaus A; Treleaven J; Delord C; Cross NC; Goldman JM
Leukemia; 1995 Feb; 9(2):329-35. PubMed ID: 7869772
[TBL] [Abstract][Full Text] [Related]
2. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
[TBL] [Abstract][Full Text] [Related]
3. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome].
Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A
Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143
[TBL] [Abstract][Full Text] [Related]
4. Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia.
Tuszynski A; Dhut S; Young BD; Lister TA; Rohatiner AZ; Amess JA; Chaplin T; Dorey E; Gibbons B
Leukemia; 1993 Oct; 7(10):1504-8. PubMed ID: 8412311
[TBL] [Abstract][Full Text] [Related]
5. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
[TBL] [Abstract][Full Text] [Related]
6. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
[TBL] [Abstract][Full Text] [Related]
7. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
8. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay.
Yokota H; Tsuno NH; Tanaka Y; Fukui T; Kitamura K; Hirai H; Osumi K; Itou N; Satoh H; Okabe M; Nakahara K
Leukemia; 2002 Jun; 16(6):1167-75. PubMed ID: 12040449
[TBL] [Abstract][Full Text] [Related]
9. P190-type bcr/abl expressed in myeloid colonies in a patient with Ph1-positive acute lymphoblastic leukemia.
Sadamura S; Umemura T; Hirata J; Takahira H; Yufu Y; Abe Y; Nishimura J; Nawata H
Leukemia; 1992 Aug; 6(8):791-5. PubMed ID: 1640730
[TBL] [Abstract][Full Text] [Related]
10. [Sequential analysis of p210- and p190-bcr-abl by RT-PCR after allogeneic bone marrow transplantation for p210/p190-bcr-abl double positive acute lymphoblastic leukemia].
Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Motomura S; Kodama F; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2001 Feb; 42(2):89-93. PubMed ID: 11280922
[TBL] [Abstract][Full Text] [Related]
11. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
Kohler S; Galili N; Sklar JL; Donlon TA; Blume KG; Cleary ML
Leukemia; 1990 Aug; 4(8):541-7. PubMed ID: 2201832
[TBL] [Abstract][Full Text] [Related]
12. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
[TBL] [Abstract][Full Text] [Related]
13. Polymerase chain reaction: a method for monitoring tumor cell purge by long-term culture in BCR/ABL positive acute lymphoblastic leukemia.
Fabrega S; Laporte JP; Giarratana MC; Douay L; Fouillard L; Da WM; Perrot C; Barbu V; Gorin NC
Bone Marrow Transplant; 1993 Feb; 11(2):169-73. PubMed ID: 8435666
[TBL] [Abstract][Full Text] [Related]
14. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Tabayashi T; Yamada K; Takeuchi M
Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
[TBL] [Abstract][Full Text] [Related]
15. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Schulze E; Krahl R; Thalmeier K; Helbig W
Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
Leukemia; 1997 Apr; 11 Suppl 3():541-4. PubMed ID: 9209451
[TBL] [Abstract][Full Text] [Related]
17. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
[TBL] [Abstract][Full Text] [Related]
18. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
19. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
[TBL] [Abstract][Full Text] [Related]
20. Undifferentiated immunophenotypes and not expression of BCR-ABL can be associated in adult Mestizo Mexican patients with ALL.
Vázquez-Franco JE; Reyes-Maldonado E; Montiel-Cervantes LA; Lezama RA
Rev Invest Clin; 2012; 64(1):32-9. PubMed ID: 22690527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
